WEGOVY weight loss study aims to predict who benefits most
NCT ID NCT05897398
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study followed 1100 adults with severe obesity who took WEGOVY (semaglutide) for 12 months. Researchers collected data on weight, eating habits, and blood markers to see how the drug worked in different groups. The goal is to use this information, along with artificial intelligence, to identify which patients are most likely to lose significant weight. This is an observational study, so it looks at real-world outcomes rather than testing a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
WEGOVY (semaglutide)
What this could lead to
If successful, this study could help doctors predict which patients with severe obesity will lose the most weight with WEGOVY, leading to more personalized treatment.
What could go wrong
This is an observational study, not a controlled trial, so results may not prove cause and effect. Weight loss varies widely, and the findings may not apply to all obesity types.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Espace Médical Nutrition & Obésité (EMNO) Maison Médicale Valmy
Dijon, 21000, France
-
Service Endocrinologie Diabète Nutrition Hôpitaux de Brabois - CHU Nancy
Vandœuvre-lès-Nancy, 54500, France
-
Service Endocrinologie Diabétologie CHU de Grenoble
La Tronche, 38250, France
-
Service Endocrinologie Diabétologie Maladies Métaboliques CHU François Mitterrand Dijon
Dijon, 21079, France
-
Service Endocrinologie Diabétologie Nutrition APHP - Hôpital Jean Verdier
Bondy, 93140, France
-
Service Endocrinologie Diabétologie Nutrition CHU Poitiers
Poitiers, 86021, France
-
Service Endocrinologie Diabétologie Nutrition CHU de Nantes - Hôpital Guillaume & René Laennec
Nantes, 44093, France
-
Service Endocrinologie Diabétologie Nutrition Hôpital Lapeyronie - CHU Montpellier
Montpellier, 34295, France
-
Service Endocrinologie Hôpital Conception - APHM
Marseille, 13385, France
-
Service Endocrinologie Hôpital Haut Léveque - CHU Bordeaux
Pessac, 33604, France
-
Service Endocrinologie, Maladies Métaboliques et Nutrition Hôpital Rangueil (CHU Toulouse)
Toulouse, 31059, France
-
Service Nutrition APHP - GHU Pitié Salpêtrière
Paris, 75013, France
-
Service Nutrition Diabétologie Endocrinologie APHP - Hôpital Européen Georges-Pompidou (HEGP)
Paris, 75015, France
-
Service de chirurgie APHP - GHU Nord Hôpital Louis Mourier
Colombes, 92700, France